Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells

Top
Topic: Anticancer Strategies Affecting Tumor Progression

A special issue of Journal of Cancer Metastasis and Treatment

ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)

Submission deadline: 30 Nov 2022

Guest Editor(s)

  • Marzia Bruna Gariboldi, PhD
    Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.

    Website | E-mail

Special Issue Introduction

Despite decade-long studies and advancements in anticancer therapeutic regimens, cancer is still one of the most lethal diseases that affect hundreds of millions of patients in the world on a daily basis. The common cancer treatment paradigm includes chemotherapy, surgery, radiation therapy, and biological therapy. However, cancer formation is a highly regulated and complex process, largely dependent on its microenvironment. This complexity highlights the need for developing novel therapies, such as target-based treatment depending on cancer phenotype and genotype, small molecules-based chemotherapy, and immunotherapy. 

Aimed topics can be, but are not confined to:
- Strategies inducing tumor cell death or ICD;
- Tumor progression inhibitors;
- Novel anticancer drugs;
- Inhibition of the epithelial-mesenchymal transition.

Submission Deadline

30 Nov 2022

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=jcmt&SpecialIssueId=jcmt20220516
Submission Deadline: 31 Nov 2022
Contacts: Ivory Ma, Assistant Editor, ivory@jcmtjournal.com

Published Articles

none
© 2016-2022 OAE Publishing Inc., except certain content provided by third parties